MSD India launches 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL 9

India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys

FDA approves first immunotherapy for recurrent respiratory papillomatosis

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally

WHO endorses Roche’s dual-stain cytology testing in its cervical cancer prevention guidelines

Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results

Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9

The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9

Gavi outlines plans to support access to new vaccines

The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030

Merck plans to conduct clinical trials of a novel investigational HPV vaccine for GARDASIL9

Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers

Dr Mandaviya delivers keynote address at 5th Foundation Day of National Cancer Institute, AIIMS Jhajjar

Launches collaborative centre for translational research in head and neck cancer

Serum Institute of India likely front-runner to win supply of HPV vaccines for UIP, says GlobalData

The Indian government will float a global tender in April 2023 to procure HPV vaccines.

Merck recognized on Fortune’s 2022 change the World List

This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.